Karyopharm Therapeutics (KPTI) EBT Margin (2012 - 2025)
Karyopharm Therapeutics (KPTI) reported EBT Margin of 264.44% for Q4 2025, up 11528.0% on a YoY basis from N/an in Q4 2024, and up 451.95% quarter-over-quarter from 75.14% in Q3 2025.
Karyopharm Therapeutics (KPTI) EBT Margin (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported EBT Margin for 14 years, with the latest figure at 264.44% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin rose 11528.0% year-over-year to 264.44%; the trailing twelve-month figure through Dec 2025 stood at 2.47% (down 253.0% YoY), and the FY2025 full-year result was 2.47%, down 253.0% from the prior year.
- EBT Margin for Q4 2025 stood at 264.44%, up from 75.14% in the prior quarter.
- The five-year high for EBT Margin was 264.44% in Q4 2025, with the low at 246.2% in Q1 2021.
- Historically, EBT Margin has averaged 68.06% across 5 years, with a median of 91.92% in 2023.
- Annual changes were most pronounced in 2021 — EBT Margin tumbled 27474 bps — and 2024, when it surged 27275 bps.
- Karyopharm Therapeutics' EBT Margin stood at 54.37% in 2021, then plunged by 311 bps to 114.45% in 2022, then slipped by 8 bps to 123.59% in 2023, then surged by 221 bps to 149.16% in 2024, then jumped by 77 bps to 264.44% in 2025.
- The last three EBT Margin figures came in at 264.44% (Q4 2025), 75.14% (Q3 2025), and 98.11% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | 264.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 264.44% |
| Sep 30, 2025 | -75.14% |
| Jun 30, 2025 | -98.11% |
| Mar 31, 2025 | -78.05% |
| Dec 31, 2024 | 149.16% |
| Sep 30, 2024 | -82.62% |
| Jun 30, 2024 | 55.76% |
| Mar 31, 2024 | -112.57% |
| Dec 31, 2023 | -123.59% |
| Sep 30, 2023 | -95.79% |
| Jun 30, 2023 | -86.49% |
| Mar 31, 2023 | -88.05% |
| Dec 31, 2022 | -114.45% |
| Sep 30, 2022 | -100.37% |
| Jun 30, 2022 | -123.34% |
| Mar 31, 2022 | -86.57% |
| Dec 31, 2021 | 54.37% |
| Sep 30, 2021 | -137.19% |
| Jun 30, 2021 | -236.49% |
| Mar 31, 2021 | -246.20% |